Christopher J. Nardo
Equibles does not estimate personal net worth.
Get an email with a short summary when Dermata Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DRMA alertsAbout Christopher J. Nardo
The proxy statement of Dermata Therapeutics, Inc. reports total compensation of $492,680 for Christopher J. Nardo in fiscal 2024, including a base salary of $349,500. Disclosed compensation is on record for 2 fiscal years. Dermata Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Dermata Therapeutics, Inc. includes Gerald T. Proehl (CEO and Board Member), Kyri K. Van Hoose (CFO), Kyri Van Hoose (CFO) and 7 others.
Affiliation history
-
Dermata Therapeutics, Inc. (DRMA)
Proxy statement
CurrentStart not stated–present
Last confirmed April 17, 2026
Company network
Leadership on record at Dermata Therapeutics, Inc.
- Gerald T. Proehl CEO, Board Member
- Kyri K. Van Hoose CFO
- Kyri Van Hoose CFO
- Andrew Sandler Board Member
- Brittany Bradrick Board Member
- David Hale Board Member
- Kathleen Scott Board Member
- Steven Mento Board Member
- Steven Mento, Ph.D. Board Member
- To approve Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Dermata Therapeutics, Inc. (DRMA) | Senior Vice President, Chief Development Officer | $349,500 | $492,680 |
| 2023 | Dermata Therapeutics, Inc. (DRMA) | Senior Vice President, Chief Development Officer | $336,000 | $469,970 |
Recent activity
No call appearances or filed executive changes recorded yet.